Validation of ClarityDX Prostate as a Reflex Test to Refine the Prediction of Clinically-significant Prostate Cancer

This ambispective observational cohort study will evaluate the clinical performance of the ClarityDX Prostate blood test in men with a prostate-specific antigen (PSA) level of 3 ng/mL or higher who are undergoing prostate biopsy due to suspicion of prostate cancer. The study will compare ClarityDX Prostate test results with biopsy outcomes to determine the test's ability to identify the presence of clinically significant prostate cancer.

Inclusion Criteria: 1. Males between 40-75 (inclusive) years of age; 2. With and without family history of prostate cancer; 3. No prior prostate cancer diagnosis and who are referred to have a prostate biopsy; 4. Total PSA results \>/= 3ng/mL collected within 6m of enrollment; 5. Willing to permit provincial agencies (e.g. Alberta Health Services, Alberta Health, Netcare, Service Alberta or other based on recruitment jurisdiction) to disclose health-related information to study; 6. Undergoing a diagnostic prostate biopsy; and 7. Provided informed consent to participate in the study. Exclusion Criteria: 1. Unwilling to participate in the study; 2. Unavailable for biopsy procedure in recruitment areas; 3. Not undergoing a prostate biopsy; 4. Prior diagnosis of cancer excluding non-melanoma skin cancer; and/or 5. Under the age of 40 years of age or over the age of 75 years of age.